![]() |
市場調查報告書
商品編碼
2088589
泌尿系統市場:全球市場預測(依產品類型、技術、疾病類型、通路和最終用戶分類)-2026-2032年Urology Market by Product Type, Technology, Condition Type, Distribution Channel, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,泌尿系統市場將成長至 1,398.5 億美元,複合年成長率為 11.74%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 642.8億美元 |
| 預計年份:2026年 | 712.5億美元 |
| 預測年份 2032 | 1398.5億美元 |
| 複合年成長率 (%) | 11.74% |
由於疾病發生率上升、人口老化以及微創泌尿系統手術的快速普及,泌尿系統市場正在改變。根據國際癌症研究機構(IARC)發布的《2022年全球癌症監測報告》(GLOBOCAN 2022),全球整體新增前列腺癌病例約147萬例,膀胱癌病例超過61.4萬例,腎癌病例近43.5萬例。這些數據凸顯了對泌尿系統診斷、內視鏡檢查、機器人手術、體外震波碎石術、良性前列腺增生治療、尿失禁護理和泌尿系統腫瘤治療服務的持續需求。
泌尿系統領域正從開放性手術和臨時治療轉向微創、數據驅動和指南導向的治療路徑。機器人輔助手術、軟性輸尿管鏡檢查、雷射碎石術、磁振造影導引前列腺切片檢查、局部治療和門診內視鏡檢查等技術在提高治療精準度的同時,也幫助醫院應對容量和成本壓力。
人工智慧(AI)已不再只是一個獨立的解決方案,它正成為泌尿系統領域一股實際的驅動力。人工智慧驅動的影像診斷、病理分流、手術規劃、預測分析和遠端監測等技術正在接受評估,旨在提高診斷的一致性並簡化工作流程。在前列腺癌領域,人工智慧最突出的應用體現在磁振造影(MRI)判讀和數位病理學方面,其目標是減少診斷差異並支持風險分層。
亞太地區泌尿系統領域正經歷高速成長,這主要受人口老化、私立醫院網路擴張以及前列腺、腎臟和膀胱疾病診斷數量增加的推動。儘管內視鏡、雷射系統、機器人平台和泌尿系統腫瘤診斷技術在中國、印度、日本、韓國和澳洲的應用正在加速,但不同醫療體系在保險覆蓋範圍和專科醫生資源方面仍存在顯著差異。
東協市場受益於醫療基礎設施的不斷發展、醫療旅遊的興起以及內視鏡手術的普及,其中新加坡、泰國、馬來西亞、印尼和越南在購買力、臨床能力和監管成熟度方面各有不同。海灣合作理事會(GCC)國家優先發展先進的醫院設施、本地化專科醫療服務以及數位化醫療基礎設施,這使得該地區成為高價值泌尿系統醫療設備、機器人手術項目和複雜泌尿系統腫瘤治療服務的理想市場。
美國在機器人輔助泌尿系統手術、先進影像技術、分子診斷和臨床試驗方面處於主導地位,這得益於其大型學術醫療中心和完善的保險報銷管道。加拿大在其公共醫療體系中強調價值觀、實證實踐和公平獲取醫療服務,而墨西哥和巴西的私人醫院對微創泌尿系統治療、結石治療和前列腺護理的需求強勁。
行業領導者應優先考慮臨床證據、醫生教育以及與治療總成本相關的訊息。能夠減少住院時間、再次治療、感染風險、輻射暴露和手術差異的產品將為醫院、保險公司和專科診所帶來顯著優勢。
本執行摘要是基於對公開可查資料的三角檢驗,這些資料包括世界衛生組織和國際癌症研究機構全球癌症研究網路(IARC GLOBOCAN)的癌症統計數據、經合組織和各國醫療保健支出資料集、美國食品藥物管理局(FDA)和歐洲藥品管理局(EMA)的監管文件,以及美國泌尿外科協會(AUA)、歐洲泌尿外科協會(EAU)、美國國家綜合癌症網路(NCCN)和英國國家衛生與臨床最佳化研究所(NICE)的臨床資訊來源。我們仔細檢驗了關於機器人手術、磁振造影引導切片檢查、結石治療、良性前列腺增生(BPH)治療、泌尿系統學和尿失禁護理的同行評審證據,以確定檢驗的行業成長要素。
人口需求、癌症負擔、微創醫學創新以及人工智慧驅動的工作流程,共同推動泌尿系統持續變革。當臨床療效、報銷機制、病患就醫便利性和營運效率達到平衡時,將湧現最大的機會。
The Urology Market is projected to grow by USD 139.85 billion at a CAGR of 11.74% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 64.28 billion |
| Estimated Year [2026] | USD 71.25 billion |
| Forecast Year [2032] | USD 139.85 billion |
| CAGR (%) | 11.74% |
The urology market is being reshaped by rising disease prevalence, aging populations, and rapid adoption of minimally invasive urology procedures. According to IARC GLOBOCAN 2022, prostate cancer accounted for about 1.47 million new cases worldwide, while bladder cancer exceeded 614,000 new cases and kidney cancer approached 435,000 new cases. These figures reinforce sustained demand for urology diagnostics, endoscopy, robotic surgery, stone management, benign prostatic hyperplasia treatment, urinary incontinence care, and uro-oncology services.
Clinical demand is also expanding beyond cancer. NIDDK reports that benign prostatic hyperplasia becomes increasingly common with age, and kidney stones affect a substantial share of adults, with recurrence risk driving repeat care. For industry leaders, the growth opportunity lies in integrating evidence-based devices, diagnostics, pharmaceuticals, and digital workflows that reduce complications, shorten hospital stays, and improve patient-centered outcomes.
The urology landscape is shifting from open surgery and episodic care toward minimally invasive, data-enabled, and guideline-directed treatment pathways. Robotic-assisted surgery, flexible ureteroscopy, laser lithotripsy, MRI-targeted prostate biopsy, focal therapies, and outpatient endoscopic procedures are improving precision while helping hospitals manage capacity and cost pressures.
Payment models and regulatory expectations are also changing. Providers and manufacturers are increasingly expected to demonstrate real-world evidence, long-term safety, and measurable quality outcomes. As a result, urology companies that align innovation with clinical guidelines from organizations such as the AUA, EAU, NCCN, and NICE are better positioned to secure adoption, reimbursement, and physician trust.
Artificial intelligence is becoming a practical enabler in urology rather than a standalone solution. AI-supported imaging review, pathology triage, operative planning, predictive analytics, and remote monitoring are being evaluated to improve diagnostic consistency and workflow efficiency. In prostate cancer, AI applications are most visible in MRI interpretation and digital pathology, where the goal is to reduce variability and support risk stratification.
The cumulative impact of AI will depend on validated datasets, regulatory oversight, cybersecurity, and clinician accountability. FDA guidance on software as a medical device and good machine learning practice indicates that successful AI deployment must be transparent, monitored after launch, and integrated into clinical decision-making without replacing physician judgment.
Asia-Pacific is a high-growth urology region driven by population aging, expanding private hospital networks, and rising diagnosis of prostate, kidney, and bladder conditions. China, India, Japan, South Korea, and Australia are accelerating adoption of endoscopy, laser systems, robotic platforms, and uro-oncology diagnostics, although reimbursement depth and specialist availability vary widely across health systems.
North America remains a leading region for premium urology technologies due to high healthcare expenditure, strong academic medical centers, FDA-regulated innovation, and widespread use of robotic surgery and advanced imaging. Latin America is gaining momentum through private-sector investment and urban specialty centers, with Brazil and Mexico serving as key adoption hubs for minimally invasive urology, kidney stone management, and BPH treatment.
Europe shows steady demand supported by EAU-guided clinical practice, cancer screening discussions, centralized procurement, and growing emphasis on value-based purchasing under the EU Medical Device Regulation. The Middle East, especially GCC countries, is investing in tertiary hospitals, specialty care localization, and medical tourism, while Africa presents long-term demand linked to underdiagnosis, workforce constraints, late-stage cancer presentation, and the need for scalable access to essential urology services.
ASEAN markets are benefiting from healthcare infrastructure upgrades, medical tourism, and broader access to endoscopic procedures, with Singapore, Thailand, Malaysia, Indonesia, and Vietnam contributing different levels of purchasing power, clinical capacity, and regulatory maturity. GCC countries are prioritizing advanced hospital capacity, specialty care localization, and digital health infrastructure, making the group attractive for high-value urology devices, robotic surgery programs, and complex uro-oncology services.
The European Union is shaped by harmonized regulatory expectations, health technology assessment, and strong guideline adherence, which favor suppliers with robust clinical evidence, quality systems, and post-market surveillance. BRICS economies offer scale, expanding specialty hospital networks, and rising procedure volumes, but successful access requires localized pricing, service networks, physician training, and public-sector engagement.
G7 countries continue to influence urology clinical standards, reimbursement evidence, screening policy discussions, and early adoption of premium technologies, including robotic-assisted surgery and AI-supported diagnostics. NATO members add importance to supply-chain resilience, cybersecurity, equipment continuity, and trusted digital infrastructure as connected surgical platforms, imaging systems, and remote monitoring tools become more embedded in urology care pathways.
The United States leads in robotic urologic surgery, advanced imaging, molecular diagnostics, and clinical trial activity, supported by major academic centers and established reimbursement channels. Canada emphasizes public health system value, evidence-based adoption, and equitable access, while Mexico and Brazil show strong private hospital demand for minimally invasive urology, stone management, and prostate care.
The United Kingdom, Germany, France, Italy, and Spain are influenced by national health technology assessment, EAU-aligned practice, cancer pathway reforms, and growing pressure to reduce waiting lists. Germany and France maintain strong hospital infrastructure and specialist capacity, while the United Kingdom continues to emphasize guideline-based diagnostics, and Italy and Spain show sustained demand for endourology, BPH treatment, and uro-oncology services.
Russia maintains significant demand for urology services despite procurement, reimbursement, and access complexities. China is scaling domestic innovation, hospital modernization, and cancer diagnostics; India is expanding affordable specialty care across metropolitan and tier-two cities; and Japan remains a mature market with aging-driven BPH, incontinence, kidney stone, and cancer demand. Australia and South Korea demonstrate strong adoption of evidence-based technology, with South Korea particularly active in surgical innovation, digital health integration, and high-volume specialty care.
Industry leaders should prioritize clinical evidence, physician education, and total-cost-of-care messaging. Products that reduce length of stay, retreatment, infection risk, radiation exposure, and procedural variability will be better positioned with hospitals, payers, and specialist practices.
Organizations should localize go-to-market models by region, pairing premium platforms with service contracts, training, workflow support, and flexible financing in growth markets. Leaders should also build AI governance, cybersecurity readiness, data interoperability, and post-market evidence systems before scaling connected urology solutions across imaging, surgery, diagnostics, and remote patient monitoring.
This executive summary is based on triangulation of publicly available and verifiable sources, including WHO and IARC GLOBOCAN cancer statistics, OECD and national health expenditure datasets, FDA and EMA regulatory materials, and clinical guidelines from AUA, EAU, NCCN, and NICE. Peer-reviewed evidence on robotic surgery, MRI-targeted biopsy, stone management, BPH treatment, uro-oncology, and urinary incontinence care was reviewed to identify validated industry drivers.
The methodology emphasizes source reliability, recency, and clinical relevance. Insights were synthesized through epidemiology assessment, regional policy review, technology adoption analysis, reimbursement environment evaluation, and regulatory landscape interpretation to provide decision-useful content for urology stakeholders.
Urology is entering a period of sustained transformation as demographic demand, cancer burden, minimally invasive innovation, and AI-enabled workflows converge. The strongest opportunities will emerge where clinical outcomes, reimbursement evidence, patient access, and operational efficiency are aligned.
Organizations that combine validated technology with regional execution, physician engagement, service reliability, and robust data governance will be best positioned to advance the global urology market while improving quality of care for patients with cancer, kidney stones, BPH, incontinence, and complex urinary disorders.